Skip to main content

Table 3 Cytogenetic abnormalities of MDS patients stratified by age groups

From: Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia

 Total (n = 93)Younger MDS patients (n = 50)Older MDS patients (n = 43)p value
Genes mutation total events (mean)1.781.641.950.216
 TET272 (77.4%)41 (82.0%)31 (72.1%)0.255
 ASXL121 (22.6%)10 (20.0%)11 (25.6%)0.521
 U2AF118 (19.4%)10 (20.0%)9 (20.9%)0.912
 RUNX19 (9.7%)3 (6.0%)6 (14.0%)0.196
 NRAS7 (7.5%)2 (4.0%)5 (11.6%)0.164
 TP535 (5.4%)2 (4.0%)3 (7.0%)0.526
 SF3B15 (5.4%)2 (4.0%)3 (7.0%)0.526
 DNMT3A5 (5.4%)2 (4.0%)3 (7.0%)0.526
 CEBPA5 (5.4%)3 (6.0%)2 (4.7%)0.774
 SRSF25 (5.4%)0 (0%)5 (11.6%)N/A
 ETV64 (4.3%)3 (6%)1 (2%)0.384
 SETBP13 (3.2%)2 (4%)1 (2%)0.649
 JAK22 (2.3%)0 (0%)2 (5%)N/A
 PHF61 (1.1%)0 (0%)1 (2%)N/A
 NPM11 (1.1%)0 (0%)1 (2%)N/A
 IDH21 (1.1%)0 (0%)1 (2%)N/A
 EZH21 (1.1%)1 (2%)0 (0%)N/A
 CBL1 (1.1%)1 (2%)0 (0%)N/A
DNA methylation (frequency, %)72 (77.4%)41 (82%)31 (72.1%)0.547
RNA spliceosome (frequency, %)28 (30.1%)12 (24%)16 (37.2%)0.166
Chromatin remodelling (frequency, %)22 (23.7%)11 (22%)11 (25.6%)0.685
Transcriptional deregulation (frequency, %)14 (15.1%)6 (12%)8 (18.6%)0.375
Activated signalling (frequency, %)10 (10.8%)3 (6%)7 (16.3%)0.111